Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Michelle H. Townsend"'
Publikováno v:
Cell & Bioscience, Vol 10, Iss 1, Pp 1-16 (2020)
Abstract Proliferation markers, such as proliferating cell nuclear antigen (PCNA), Ki-67, and thymidine kinase 1 (TK1), have potential as diagnostic tools and as prognostic factors in assessing cancer treatment and disease progression. TK1 is involve
Externí odkaz:
https://doaj.org/article/6fc14cad9de6445aad0fc2c1c23a6cac
Autor:
Michelle H. Townsend, Zac E. Ence, Taylor P. Cox, John E. Lattin, Weston Burrup, Michael K. Boyer, Stephen R. Piccolo, Richard A. Robison, Kim L. O’Neill
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background The aim of this study is to determine whether Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) could be used as a biomarker for the diagnosis and treatment of B cell malignancies. With 4.3% of all new cancers diagnosed as Non
Externí odkaz:
https://doaj.org/article/67a3eff2e7cf4eb580f334fd9da89878
Autor:
Edwin J. Velazquez, Taylor D. Brindley, Gajendra Shrestha, Eliza E. Bitter, Jordan D. Cress, Michelle H. Townsend, Bradford K. Berges, Richard A. Robison, K. Scott Weber, Kim L. O’Neill
Publikováno v:
Cancer Cell International, Vol 20, Iss 1, Pp 1-20 (2020)
Abstract Background Thymidine kinase 1 (TK1) is a pyrimidine salvage pathway enzyme that is up-regulated in malignant tissues and elevated in the serum of cancer patients. While TK1 has been well established as a tumor biomarker, little has been done
Externí odkaz:
https://doaj.org/article/ce40312a18834b01b2066911b7b8d49a
Autor:
Michelle H. Townsend, Abigail M. Felsted, Zac E. Ence, Stephen R. Piccolo, Richard A. Robison, Kim L. O’Neill
Publikováno v:
Molecular & Cellular Oncology, Vol 6, Iss 2, Pp 1-10 (2019)
HPRT is a housekeeping enzyme involved in recycling guanine and inosine in the purine salvage pathway. As a housekeeping gene, HPRT has been widely used as an endogenous control for molecular studies evaluating changes in gene expression. Yet, recent
Externí odkaz:
https://doaj.org/article/fcba7383230242058ab0e332506342b9
Autor:
Michelle H. Townsend, Zac E. Ence, Abigail M. Felsted, Alyssa C. Parker, Stephen R. Piccolo, Richard A. Robison, Kim L. O’Neill
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-18 (2019)
Abstract Background Incidence of endometrial cancer are rising both in the United States and worldwide. As endometrial cancer becomes more prominent, the need to develop and characterize biomarkers for early stage diagnosis and the treatment of endom
Externí odkaz:
https://doaj.org/article/14e17277c61d421ab95c767ed48d207a
Autor:
Evita G. Weagel, Weston Burrup, Roman Kovtun, Edwin J. Velazquez, Abigail M. Felsted, Michelle H. Townsend, Zachary E. Ence, Erica Suh, Stephen R. Piccolo, K. Scott Weber, Richard A. Robison, Kim L. O’Neill
Publikováno v:
Cancer Cell International, Vol 18, Iss 1, Pp 1-14 (2018)
Abstract Background Lung, breast, and colorectal malignancies are the leading cause of cancer-related deaths in the world causing over 2.8 million cancer-related deaths yearly. Despite efforts to improve prevention methods, early detection, and treat
Externí odkaz:
https://doaj.org/article/19a1ea04c5ef44dc9c6502688b1a429a
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-23 (2018)
Abstract Biomarkers are an integral part of cancer management due to their use in risk assessment, screening, differential diagnosis, prognosis, prediction of response to treatment, and monitoring progress of disease. Recently, with the advent of Chi
Externí odkaz:
https://doaj.org/article/12e489dffe2b4678a9090b0ab1a5150e
Publikováno v:
Molecular & Cellular Oncology, Vol 5, Iss 4 (2018)
The aim of this study is to investigate these enzymes as possible biomarkers in two colorectal cancer cell lines: HT29, SW480, SW620, and Colo205. With 1,168,929 individuals currently diagnosed with colorectal cancer in the United States, there remai
Externí odkaz:
https://doaj.org/article/c041d9bd97d04a1fa709c6d8ef773601
Autor:
Evita G. Weagel, Weston Burrup, Roman Kovtun, Edwin J. Velazquez, Abigail M. Felsted, Michelle H. Townsend, Zachary E. Ence, Erica Suh, Stephen R. Piccolo, K. Scott Weber, Richard A. Robison, Kim L. O’Neill
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-1 (2019)
Following publication of the original article [1], the authors would like to make an amendment to the Acknowledgements section.
Externí odkaz:
https://doaj.org/article/211cbcb8c4e14c419fe6cc189b9478bb
Publikováno v:
Immunologic Research. 68:63-70
With several different CAR T cell therapies under advanced phases of clinical trials, and the first FDA-approved CAR treatments in 2017 (Yescarta and Kymriah), CAR T cell therapy has become one of the most promising therapies for the treatment of cer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c524c0912052daa88fb7a7db042bbbd
https://doi.org/10.1007/s12026-020-09119-7
https://doi.org/10.1007/s12026-020-09119-7